Market Access Strategy
The success of market access for healthcare products and services is related to the value compared with established standards of care. Hello Healthcare enables you to identify the measures needed for successful access to the German healthcare system.
Knowing the right people and how to approach them, together with stakeholder-specific communications drive the implementation of successful market access and reimbursement strategies. Hello Healthcare supports you in identifying the relevant experts, building networks and developing the targeted key messages and dossiers.
To realize the economic potential of healthcare products and services requires coverage by public or private payers (Gesetzliche Krankenversicherung [GKV] and Private Krankenversicherung [PKV] in Germany), patients or insurers, and this reimbursement is a key part of your market access strategy. Hello Healthcare provides a portfolio of services to identify and support key reimbursement activities, such as targeted tariffs (DRGs, ZEs) and codes (EBM, GOAE), NUB campaigns, and direct contracting.
Health Technology Assessments (HTA) and value dossiers
Applications for market access or reimbursement increasingly require systematic reviews and standardized health technology assessments (HTA). Value dossiers enable the communication of economic benefits of healthcare products and services to stakeholders from healthcare professionals to payers and regulators. Hello Healthcare provides quality HTA reports and dossiers to drive your market access strategy and communication.
Health Economic Evaluations
Clinicians, payers and regulators are increasingly assessing the value of pharmaceuticals, medical devices, and diagnostics in terms of their clinical and economic outcomes. Health economic data based on well-conceived and conducted studies can be used to support successful marketing and market access strategies. Hello Healthcare offers a broad range of services for health economic evaluations and outcomes research, including cost-effectiveness and cost-benefit analyses.